ZYVOX IS A CLEAR CHOICE TO TREAT INFECTIONS CAUSED BY MRSA
ZYVOX has been used to treat an estimated 1 million patients across indications worldwide.1
* ZYVOX was proven effective in infections due to MRSA in the largest MRSA study to date2
* ZYVOX delivers efficacy in a range of infections:
NP, including VAP
cSSSI
DFI*
* ZYVOX offers flexibility due to the 100% bioavailable oral therapy
o Seamless transition from IV to oral
o The benefits of an oral formulation
o Shorter IV duration, earlier hospital discharge1,3
* ZYVOX offers a favorable safety profile in a broad range of patients
The past 5 years have shown that for MRSA infections, resistance to ZYVOX is rare.
* National research facilities have continuously demonstrated that resistance to ZYVOX is low1
* ZYVOX inhibits bacterial protein synthesis through a mechanism of action different from that of other antibacterial agents; therefore, cross-resistance between ZYVOX and other classes of antibiotics is unlikely
*Without concomitant osteomyelitis.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZYVOX and other antibacterial drugs, ZYVOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
* ZYVOX was proven effective in infections due to MRSA in the largest MRSA study to date2
* ZYVOX delivers efficacy in a range of infections:
NP, including VAP
cSSSI
DFI*
* ZYVOX offers flexibility due to the 100% bioavailable oral therapy
o Seamless transition from IV to oral
o The benefits of an oral formulation
o Shorter IV duration, earlier hospital discharge1,3
* ZYVOX offers a favorable safety profile in a broad range of patients
The past 5 years have shown that for MRSA infections, resistance to ZYVOX is rare.
* National research facilities have continuously demonstrated that resistance to ZYVOX is low1
* ZYVOX inhibits bacterial protein synthesis through a mechanism of action different from that of other antibacterial agents; therefore, cross-resistance between ZYVOX and other classes of antibiotics is unlikely
*Without concomitant osteomyelitis.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZYVOX and other antibacterial drugs, ZYVOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.